<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>P53 inactivation is often observed in Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) cells due to mutations in the p53 gene or overexpression of its negative regulator, murine double minute-2 (MDM2) </plain></SENT>
<SENT sid="1" pm="."><plain>This event is now considered an essential part of the oncogenic process </plain></SENT>
<SENT sid="2" pm="."><plain>Epstein-Barr virus (EBV) is strongly associated with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> and is a cofactor in its development </plain></SENT>
<SENT sid="3" pm="."><plain>We previously showed that <z:chebi fb="0" ids="46742">nutlin-3</z:chebi>, an <z:chebi fb="68" ids="48706">antagonist</z:chebi> of MDM2, activates the p53 pathway in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell lines harboring <z:mp ids='MP_0002169'>wild-type</z:mp> p53 </plain></SENT>
<SENT sid="4" pm="."><plain>However, <z:chebi fb="0" ids="46742">nutlin-3</z:chebi> strongly induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in EBV (-) or latency I EBV (+) cells, whereas latency III EBV (+) cells were much more resistant </plain></SENT>
<SENT sid="5" pm="."><plain>We show here that this resistance to <z:mpath ids='MPATH_3'>apoptosis</z:mpath> is also observed in latency III EBV (+) lymphoblastoid cell lines </plain></SENT>
<SENT sid="6" pm="."><plain>We also show that, in latency III EBV (+) cells, B-cell lymphona 2 (Bcl-2) is selectively overproduced and interacts with Bcl-2-associated X protein (Bax), preventing its activation </plain></SENT>
<SENT sid="7" pm="."><plain>The treatment of these cells with the Bcl-2-homology domain 3 mimetic <z:chebi fb="5" ids="53329">ABT</z:chebi>-737 disrupts Bax/Bcl-2 interaction and allows Bax activation by <z:chebi fb="0" ids="46742">nutlin-3</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>Furthermore, treatment with these two compounds strongly induces <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="9" pm="."><plain>Thus, a combination of Mdm2 and Bcl-2 inhibitors might be a useful anti-<z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> strategy for diseases linked to <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> </plain></SENT>
</text></document>